Atypical and anaplastic meningiomas treated with bevacizumab

Journal of Neuro-Oncology

Volumn 109, Issue 1, 2012, Pages 187-193

  Nayak, Lakshmi ^a   Iwamoto, Fabio M ^b   Rudnick, Jeremy D ^c   Norden, Andrew D ^d   Lee, Eudocia Quant ^d   Drappatz, Jan ^d   Omuro, Antonio ^a   Kaley, Thomas J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Anaplastic; Atypical; Bevacizumab; Meningioma; Vascular endothelial growth factor (VEGF)

Indexed keywords

BEVACIZUMAB; HYDROXYUREA; IMATINIB; OCTREOTIDE; PASIREOTIDE; SOM 230C; SUNITINIB; UNCLASSIFIED DRUG;

ADULT; AGED; ANAPLASTIC MENINGIOMA; ARTICLE; ATYPICAL MENINGIOMA; BLEEDING; CANCER GRADING; CANCER MORTALITY; CANCER RADIOTHERAPY; CAUSE OF DEATH; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; HUMAN TISSUE; INTRATUMORAL HEMORRHAGE; MALE; MENINGIOMA; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; RISK REDUCTION; SALVAGE THERAPY; STEREOTAXIC SURGERY; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84864286286     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-012-0886-4     Document Type: Article

References (10)

1. PY Wen E Quant J Drappatz R Beroukhim AD Norden 2010 Medical therapies for meningiomas J Neurooncol 99 365 378 20820875 10.1007/s11060-010-0349-8 1:CAS:528:DC%2BC3cXht1Sru77E
2. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) (2007) WHO classification of tumours of the central nervous system, 4th edn. IARC Press, Lyon
3. PY Wen DR Macdonald DA Reardon TF Cloughesy AG Sorensen E Galanis, et al. 2010 Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group J Clin Oncol 28 1963 1972 20231676 10.1200/JCO.2009.26.3541
4. H Yoshioka S Hama E Taniguchi K Sugiyama K Arita K Kurisu 1999 Peritumoral brain edema associated with meningioma: influence of vascular endothelial growth factor expression and vascular blood supply Cancer 85 936 944 10091773 10.1002/(SICI)1097-0142(19990215)85:4<936::AID-CNCR23>3.0.CO;2-J 1:STN:280:DyaK1M7ptVWqtg%3D%3D (Pubitemid 29077572)
5. MC Chamberlain MJ Glantz CE Fadul 2007 Recurrent meningioma: salvage therapy with long-acting somatostatin analogue Neurology 69 969 973 17785665 10.1212/01.wnl.0000271382.62776.b7 1:CAS:528:DC%2BD2sXpsFaju78%3D (Pubitemid 47366049)
6. PY Wen WK Yung KR Lamborn AD Norden TF Cloughesy LE Abrey, et al. 2009 Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08) Neurooncology 11 853 860 1:CAS:528:DC%2BC3cXotVOruw%3D%3D
7. AD Norden JJ Raizer LE Abrey KR Lamborn AB Lassman SM Chang, et al. 2010 Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma J Neurooncol 96 211 217 19562255 10.1007/s11060-009-9948-7 1:CAS:528: DC%2BC3cXpsVSjsw%3D%3D
8. TJ Kaley D Schiff S Karimi, et al. 2010 Phase II trial of sunitinib (SU011248) for recurrent meningioma Neurooncology 12 Suppl 4 iv69 iv78
9. AD Norden S Hammond J Drappatz S Phuphanich DA Reardon E Wong, et al. 2011 Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma J Clin Oncol 29 2040 10.1200/JCO.2010.32.2776
10. Reardon DA, Norden AD, Desjardins A et al (2012) Phase II study of Gleevec(R) plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. J Neurooncol 106(2):409-415